DK1003546T3 - Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon - Google Patents

Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon

Info

Publication number
DK1003546T3
DK1003546T3 DK98933344T DK98933344T DK1003546T3 DK 1003546 T3 DK1003546 T3 DK 1003546T3 DK 98933344 T DK98933344 T DK 98933344T DK 98933344 T DK98933344 T DK 98933344T DK 1003546 T3 DK1003546 T3 DK 1003546T3
Authority
DK
Denmark
Prior art keywords
treating patients
patients affected
consensus interferon
disseminated sclerosis
sclerosis
Prior art date
Application number
DK98933344T
Other languages
English (en)
Inventor
David Martin
Norman L Fischer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1003546T3 publication Critical patent/DK1003546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98933344T 1997-08-15 1998-07-15 Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon DK1003546T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist

Publications (1)

Publication Number Publication Date
DK1003546T3 true DK1003546T3 (da) 2006-10-30

Family

ID=25431058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933344T DK1003546T3 (da) 1997-08-15 1998-07-15 Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon

Country Status (17)

Country Link
US (1) US6013253A (da)
EP (1) EP1003546B1 (da)
JP (1) JP3813440B2 (da)
KR (1) KR100415636B1 (da)
CN (1) CN1183963C (da)
AT (1) ATE338563T1 (da)
AU (1) AU741074B2 (da)
CA (1) CA2299361C (da)
CY (1) CY1107314T1 (da)
DE (1) DE69835823T2 (da)
DK (1) DK1003546T3 (da)
ES (1) ES2267188T3 (da)
HU (1) HU229045B1 (da)
IL (2) IL134345A0 (da)
PT (1) PT1003546E (da)
TW (1) TW474817B (da)
WO (1) WO1999008702A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
EP3064215A1 (en) * 2002-10-16 2016-09-07 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
AU2005244448B2 (en) * 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
AU2005335900B2 (en) 2005-08-26 2012-03-29 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US8178083B2 (en) * 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
PL2234645T3 (pl) * 2007-12-20 2012-10-31 Merck Serono Sa Preparaty interferonu-beta modyfikowanego PEG
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
HUE046944T2 (hu) 2013-07-18 2020-03-30 Xalud Therapeutics Inc Készítmény gyulladásos ízületi betegség kezelésére
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
TW202537627A (zh) 2017-11-24 2025-10-01 德商馬克專利公司 用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
BR9007883A (pt) * 1989-11-29 1992-09-29 Synergen Inc Producao de inibidor de interleucina-1 humana recombinante
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
CA2118119C (en) * 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
US5932208A (en) * 1993-03-19 1999-08-03 Vacsyn S.A. Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
ATE203415T1 (de) * 1994-02-08 2001-08-15 Amgen Inc Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Also Published As

Publication number Publication date
AU741074B2 (en) 2001-11-22
DE69835823D1 (de) 2006-10-19
HU229045B1 (en) 2013-07-29
HK1030157A1 (en) 2001-04-27
CY1107314T1 (el) 2012-11-21
EP1003546A1 (en) 2000-05-31
EP1003546B1 (en) 2006-09-06
HUP0002755A2 (hu) 2000-12-28
JP3813440B2 (ja) 2006-08-23
CA2299361A1 (en) 1999-02-25
JP2001515047A (ja) 2001-09-18
ES2267188T3 (es) 2007-03-01
IL134345A0 (en) 2001-04-30
HUP0002755A3 (en) 2001-11-28
IL134345A (en) 2011-03-31
CN1267225A (zh) 2000-09-20
KR20010030563A (ko) 2001-04-16
US6013253A (en) 2000-01-11
ATE338563T1 (de) 2006-09-15
TW474817B (en) 2002-02-01
KR100415636B1 (ko) 2004-01-24
DE69835823T2 (de) 2007-08-09
WO1999008702A1 (en) 1999-02-25
CA2299361C (en) 2009-09-29
PT1003546E (pt) 2006-12-29
AU8300698A (en) 1999-03-08
CN1183963C (zh) 2005-01-12

Similar Documents

Publication Publication Date Title
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
FI950465L (fi) Läpäisevä laastari lääkityksen antamiseksi ihoon
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
DK0880350T3 (da) Behandling af dissemineret sklerose
DK0973735T3 (da) Polyaromatiske antivirale præparater
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
DK19893D0 (da) Praeparat til nasal behandling
IL161889A0 (en) Method for treating diseases with omega interferon
EE9900477A (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks
ATE249835T1 (de) Immunoregulator
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
DK0752884T3 (da) Fremgangsmåde til behandling af auto-immune sygdomme ved anvendelse af type 1 interferoner
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DK1019032T3 (da) Fremgangsmåde til at forhindre misbrug af et transdermalt terapeutisk system
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin